Home Font Size: 1 2 3 Send to a Friend
On Thursday, June 1st, Dr. Martin Phillips, Senior Vice President of Clinical Development of Morphotek will present "MORAb-009, A Phase I Study in Patients with Pancreatic Adenocarcinoma and Other Mesothelin-Bearing Tumors” at the Pancreatic Cancer Research Team Symposium at 2 p.m. This discussion will include preclinical data on the role of mesothelin in tumorigenesis and preclinical models of anti-mesothelin mAb therapy in suppressing growth of mesothelin-bearing tumors in xenograft models and clinical trials. This group meeting focuses on the identification of new targets and pathways for the diagnosis and treatment of pancreatic cancer. Mesothelin has recently been shown to be a validated target involved in the majority of pancreatic cancers. Specific antibody targeting of mesothelin results in biological and immunological responses to tumors expressing this antigen. MORAb-009 is a mesothelin-specific antibody developed by Morphotek and is currently in clinical development at Johns Hopkins.
On Sunday, June 4th, Dr. Jason Konner from Memorial Sloan Kettering, the principal investigator for MORAb-003, will present "Phase I Study of MORAb-003, A Humanized Anti-Folate Receptor-Alpha Monoclonal Antibody, in Platinum Resistant Ovarian Cancer” during the Gynecologic Cancer Session from 8:00 a.m. - 12:00 p.m. This presentation will contain data from approximately 12 evaluable patients for safety. A percentage of those patients were also evaluable for secondary endpoints of efficacy by RECIST and CA125 biomarker responses and those data will also be included in the presentation.
On Monday, June 5th, Dr. Eric Routhier from Morphotek will present "MORAb-003 Inhibits Folate-Driven Growth Mediated by the Human Folate Receptor Alpha," during the Tumor Biology and Human Genetics Session from 8:00 a.m. - 12:00 p.m. This poster contains experimental data from preclinical studies regarding the ability of folate receptor alpha (FRA) over-expression to enhance cell growth in FRA null cell lines, which is reversible by treatment with the anti-FRA antibody, MORAb-003.
June 2-6, 200642nd Annual Meeting of the American Society of Clinical Oncology
Georgia World Congress CenterAtlanta, Georgia
For more information visit: http://www.asco.orgDr. Eric Routhier, Group Leader, biochemistry will present a poster entitled “MORAb-003 inhibits folate-driven growth mediated by the human folate receptor alpha”
April 1-5, 200697th Annual Meeting of the American Association for Cancer ResearchWashington Convention CenterWashington, D.C
For more information visit: http://www.aacr.orgDr. Brad Kline, Group Leader, Morphodoma and Mammalian Genetics will present a poster entitled “Human antibodies for immunotherapy development generated via human B-cell hybridoma technology”
March 20-21, 2006 10th Annual International Inflammation & Immune Diseases Drug Discovery & Development World Summit
Hyatt Regency New BrunswickTwo Albany Street, New Brunswick, NJ 08901
For more information visit: http://www.srinstitute.com/conf_page.cfm?instance_id=27&web_id=752&pid=362Dr. Luigi Grasso, VP, R&D and Co-founder of Morphotek will attend.
November 14 - 15, 2005
Dr. Nicholas Nicolaides, President and CEO to present “Case Study Optimizing Protein Yields of Mammalian Cells through Whole Genome Evolution” on November 15, 2005 at 4.30pm
November 7 - 9, 2005Bio-Europe 2005
International Conference CenterDresden, GermanyFor more information visit: http://www.ebdgroup.com/bioeurope/Dr. Phillip Sass, EVP & COO to present. Specific details to follow.
September 26-27, 2005Monocloncal Antibodies in CancerSheraton University City3549 Chestnut StreetPhiladelphia, PA 19104For more information visit: http://www.srinstitute.com/mabsDr. Luigi Grasso, VP R&D will participate. Specific details to follow.
September 11, 2005National Ovarian Cancer Coalition - 7th Annual Carolyn A. Marks Walk for the WhisperMorphotek employees and their families participated in one of this year’s major fundraising events to promote awareness of the often-subtle symptoms of ovarian cancer. Morphotek’s lead antibody “MORAb-003” is currently being investigated for its ability to treat chemo-resistant ovarian cancer patients.
September 5-6, 2005The 2nd Annual JapanBioTech MeetingThe Grand Hyatt Hotel6-10-3 RoppongiMinato-kuTokyo, Japan 106-0032For more information visit: http://www.burrillandco.com/bio/japan_biotechDr. Phillip Sass, EVP & COO to present. Specific details to follow.